Amir NASERİ, İsmail ŞEN, Kürşad TURGUT, Mehmet Ege İNCE, Havva SÜLEYMANOĞLU, Merve ERTAN, Vedat SAĞMANLIGİL

Evre B2 Dejeneratif Mitral Kapak Hastalığı Olan Anadolu Çoban Köpeklerinde Sistol-sonu Duvar Stresi/Sistol-sonu Hacim İndeks Oranı İle Sistolik Fonksiyonun Değerlendirilmesi

Bu çalışma, evre B2 dejeneratif mitral kapak hastalığı (DMVD) olan Anadolu çoban köpeklerinde (ASHs) sistol-sonu duvar stresi/sistol-sonu hacim indeks oranı (ESWS/ESV-I) ile sistolik fonksiyonu değerlendirmek için yapıldı. Çalışmada, DMVD’li 38 yetişkin ASHs (deney grubu; 20 B1 köpek ve 18 B2 köpek) ve 30 yetişkin sağlıklı ASHs (kontrol grubu) kullanıldı. Gruplar arasında ESWS/ESV-I oranı için (B2 köpeklerinde: 0.83±0.03, aralık: 0.61-1.09, B1 köpeklerinde 1.34±0.05, aralık: 1.11-1.89, kontrol köpeklerinde 2.17±0.0 aralık: 1.91-3.02) bir örtüşme yoktu. Evre B2 DMVD’li ASH’lerde, ESWS/ESV-I oranı (≤1.09) sol ventrikül yeniden yapılanması ve sistolik disfonksiyon gelişiminde risk faktörü olarak rol oynayabilir.

The End-systolic Wall Stress/End-systolic Volume Index Ratio for Systolic Function in Anatolian Shepherd Dogs with Stage B2 Degenerative Mitral Valve Disease

This study was performed to evaluate the end-systolic wall stress/end-systolic volume index ratio (ESWS/ESV-I) for LV systolic function in Anatolian shepherd dogs (ASHs) with stage B2 degenerative mitral valve disease (DMVD). Thirty-eight adult ASHs with DMVD (experimental group; 20 B1 dogs and 18 B2 dogs) and 30 weight-matched adult healthy ASHs (control group) were used as subjects. There was no overlap for the ESWS/ESV-I ratio (0.83±0.03, range: 0.61-1.09 for B2 dogs, 1.34±0.05, range: 1.11-1.89 for B1 dogs, 2.17±0.0 range: 1.91-3.02 for the control dogs) among the groups. ESWS/ESV-I ratio (≤1.09) in ASHs with stage B2 DMVD may play a developmental role in left ventricular remodelling and risk factor for development of systolic dysfunction.

PDF

___

1. Menciotti G, Borgarelli M: Review of diagnostic and therapeutic approach to canine myxomatous mitral valve disease. Vet Sci, 4:47, 2017. DOI: 10.3390/vetsci4040047
2. Gordon SG, Saunders AB, Wesselowski SR: A symptomatic canine degenerative valve disease: Current and future therapies. Vet Clin North Am Small Anim Pract, 47, 955-975, 2017. DOI: 10.1016/j.cvsm.2017.04.003
3. Turgut K: Klinik Kedi ve Köpek Kardiyolojisi. Nobel Tıp Kitapevleri. İstanbul, Türkiye, 2017.
4. Petric AD: Myxomatous mitral valve disease in dogs - An update and perspectives. Mac Vet Rev, 38 (1): 13-20, 2015. DOI: 10.14432/j. macvetrev.2014.11.026
5. Chetboul V, Tissier R: Echocardiographic assessment of canine degenerative mitral valve disease. J Vet Cardiol, 14, 127-148, 2012. DOI: 10.1016/j.jvc.2011.11.005.
6. Alter P, Koczulla AR, Nell C, Figiel JH, Vogelmeier CF, Rominger MB: Wall stress determines systolic and diastolic function - Characteristics of heart failure. Int J Cardiol, 202, 685-693, 2016. DOI: 10.1016/j.ijcard. 2015.09.032
7. Clerfond G, Bière L, Mateus V, Grall S, Willoteaux S, Prunier F, Furber A: End-systolic wall stress predicts post-discharge heart failure after acute myocardial infarction. Arch Cardiovasc Dis, 108, 310-320, 2015. DOI: 10.1016/j.acvd.2015.01.008
8. Carabello BA, Stanton P, Nolan MD, Lockhart B, Mcguire MD: Assessment of preoperative left ventricular function in patients with mitral regurgitation: Value of the end-systolic wall stress-end-systolic volume ratio. Circulation, 64, 1212-1217, 1981.
9. Matos JM, Glaus TM: Medical treatment of canine heart failure. EJCAP, 20, 171-176, 2010.
10. Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA: Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol, 14 (1): 193-202, 2012. DOI: 10.1016/j.jvc.2012.01.008
11. Mattin MJ, Boswood A, Church DB, Lopez-Alvarez J, McGreevy PD, O’Neill DG, Thomson PC, Brodbelt DC: Prevalence of and risk factors for degenerative mitral valve disease in dogs attending primarycare veterinary practices in England. J Vet Intern Med, 29, 847-854, 2015. DOI: 10.1111/jvim.12591
12. Chetboul V, Carlos Sampedrano C, Gouni V, Nicolle AP, Pouchelon JL, Tissier R: Ultrasonographic assessment of regional radial and longitudinal systolic function in healthy awake dogs. J Vet Intern Med, 20, 885-893, 2006. DOI: 10.1111/j.1939-1676.2006.tb01802.x
13. Suzuki R, Matsumoto H, Teshima T, Mochizuki Y, Koyama H: Left ventricular geometrical differences in dogs with various stages of myxomatous mitral valve disease. J Small Anim Pract, 54, 234-239, 2013. DOI: 10.1111/jsap.12058
14. Fox PR, Oyama MA, Hezzell, MJ, Rush JE, Nguyenba TP, DeFrancesco TC, Lehmkuhl LB, Kellihan HB, Bulmer B, Gordon SG, Cunningham SM, MacGregor J, Stepien RL, Lefbom B, Adin D, Lamb K: Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay. J Vet Intern Med, 29, 171-179, 2014. DOI: 10.1111/jvim.12472
15. Strunz CMC, Marcondes-Santos M, Takada JY, Fragata FS, de Padua Mansur A: Quality of life score as a predictor of death in dogs with degenerative mitral valve disease. Arq Bras Cardiol, 108 (4): 347-353, 2017. DOI: 10.5935/abc.20170032